Literature DB >> 22321778

Synthesis, biological evaluation, and structure-activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity.

Carla M S Menezes1, Gildardo Rivera, Marina A Alves, Daniel N do Amaral, Jean Pierre B Thibaut, François Noël, Eliezer J Barreiro, Lídia M Lima.   

Abstract

The inherent morbidity and mortality caused by schistosomiasis is a serious public health problem in developing countries. Praziquantel is the only drug in therapeutic use, leading to a permanent risk of parasite resistance. In search for new schistosomicidal drugs, meclonazepam, the 3-methyl-derivative of clonazepam, is still considered an interesting lead-candidate because it has a proven schistosomicidal effect in humans but adverse effects on the central nervous system did not allow its clinical use. Herein, the synthesis, in vitro biological evaluation, and molecular modeling of clonazepam, meclonazepam, and analogues are reported to establish the first structure-activity relationship for schistosomicidal benzodiazepines. Our findings indicate that the amide moiety [N(1) H-C(2) (=O)] is the principal pharmacophoric unit of 1,4-benzodiazepine schistosomicidal compounds and that substitution on the amide nitrogen atom (N(1) position) is not tolerated.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321778     DOI: 10.1111/j.1747-0285.2012.01354.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  9 in total

Review 1.  Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Authors:  Godwin Akpeko Dziwornu; Henrietta Dede Attram; Samuel Gachuhi; Kelly Chibale
Journal:  RSC Med Chem       Date:  2020-04-06

2.  Molecular cloning and characterization of novel glutamate-gated chloride channel subunits from Schistosoma mansoni.

Authors:  Vanessa Dufour; Robin N Beech; Claudia Wever; Joseph A Dent; Timothy G Geary
Journal:  PLoS Pathog       Date:  2013-08-29       Impact factor: 6.823

Review 3.  Novel therapeutic and prevention approaches for schistosomiasis: review.

Authors:  Rashika A F El Ridi; Hatem A-M Tallima
Journal:  J Adv Res       Date:  2012-06-23       Impact factor: 10.479

4.  In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni.

Authors:  Bruno J Neves; Rodolpho C Braga; José C B Bezerra; Pedro V L Cravo; Carolina H Andrade
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

5.  A Nano-MgO and Ionic Liquid-Catalyzed 'Green' Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51).

Authors:  Sebastian Anusha; Baburajeev Cp; Chakrabhavi Dhananjaya Mohan; Jessin Mathai; Shobith Rangappa; Surender Mohan; Shardul Paricharak; Lewis Mervin; Julian E Fuchs; Mahedra M; Andreas Bender; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

6.  Non-sedating benzodiazepines cause paralysis and tissue damage in the parasitic blood fluke Schistosoma mansoni.

Authors:  Paul McCusker; Md Yeunus Mian; Guanguan Li; Michael D Olp; V V N Phani Babu Tiruveedhula; Farjana Rashid; Lalit Kumar Golani; Ranjit S Verma; Brian C Smith; James M Cook; John D Chan
Journal:  PLoS Negl Trop Dis       Date:  2019-11-15

Review 7.  Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances.

Authors:  Edilma Sanabria; Ronald Edgardo Cuenca; Miguel Ángel Esteso; Mauricio Maldonado
Journal:  Toxics       Date:  2021-02-01

Review 8.  Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.

Authors:  Amber N Edinoff; Catherine A Nix; Amira S Odisho; Caroline P Babin; Alyssa G Derouen; Salim C Lutfallah; Elyse M Cornett; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Neurol Int       Date:  2022-08-22

9.  Pyrazoline derivatives as promising novel antischistosomal agents.

Authors:  Cristiane S Morais; Ana C Mengarda; Fábio B Miguel; Karine B Enes; Vinícius C Rodrigues; Maria Cristina C Espírito-Santo; Abolghasem Siyadatpanah; Polrat Wilairatana; Mara R C Couri; Josué de Moraes
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.